Real-world use of HIF-PH inhibitors in the Japan dialysis outcomes and practice patterns study (J-DOPPS, 2019–2022)

Abstract Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel therapeutic alternative to erythropoiesis-stimulating agents (ESAs) for anemia in chronic kidney disease. Evidence regarding their real-world effectiveness is still limited. Methods We analyzed data fro...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Masahiro Eriguchi, Kazuhiko Tsuruya, Hisashi Noma, Yoshihiro Onishi, Masami Inuzuka, Kenji Harada, Masaomi Nangaku
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2026-02-01
סדרה:	BMC Nephrology
נושאים:	Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) Anemia in chronic kidney disease Maintenance hemodialysis patients Erythropoiesis-stimulating agents (ESAs) C-reactive protein (CRP)
גישה מקוונת:	https://doi.org/10.1186/s12882-026-04831-2
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!